文献速递骨质疏松与代谢性骨病

依降钙素治疗绝经后骨质疏松症女性的疗效与安全性:随机临床试验的系统评价与网状Meta分析

Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials.
PubMed 文献 · Osteoporos Int · 2019-05-01

该系统评价纳入16项随机对照试验共2754名绝经后骨质疏松症女性,评估依降钙素对骨密度变化和并发症率的影响。结果显示依降钙素联合治疗和单药治疗的疼痛评分均显著低于非降钙素药物,但单药治疗并发症率显著高于安慰剂。依降钙素联合治疗可考虑用于治疗绝经后骨质疏松症。

要点

  • 依降钙素联合治疗疼痛评分WMD为-18.93(95%CI -23.97至-13.89),显著低于非降钙素药物。
  • 依降钙素单药治疗疼痛评分WMD为-13.72(95%CI -19.51至-7.94),显著低于非降钙素药物。
  • 依降钙素单药治疗并发症率POR为8.413(95%CI 2.031至34.859),显著高于安慰剂。

核心结论

  • 基于当前证据,依降钙素联合治疗可考虑用于治疗绝经后骨质疏松症,因其在疼痛缓解和并发症方面有益。
  • 依降钙素联合治疗与非降钙素药物相比,骨折率和骨密度变化相当。
  • 需要进一步试验研究依降钙素的配方和剂量。

研究设计与样本

  • 系统评价与网状Meta分析,从六个重要数据库系统识别目标试验,仅纳入随机对照试验进行合成。
  • 共纳入16项试验,招募2754名绝经后骨质疏松症女性。
  • 两名研究者使用Cochrane偏倚风险评估工具评估合格试验质量,并独立提取数据。
  • 网状Meta分析使用Peto比值比(POR,用于处理零单元格)或加权均数差(WMD,用于连续数据)及95%置信区间(CI)和一致性H。

主要发现

  • 依降钙素治疗与非降钙素药物具有可比的骨折率和骨密度变化。
  • 依降钙素联合治疗疼痛评分WMD为-18.93(95%CI -23.97至-13.89),显著低于非降钙素药物。
  • 依降钙素单药治疗疼痛评分WMD为-13.72(95%CI -19.51至-7.94),显著低于非降钙素药物。
  • 依降钙素单药治疗并发症率POR为8.413(95%CI 2.031至34.859),显著高于安慰剂。
  • 非降钙素药物并发症率Peto OR为7.450(95%CI 1.479至37.530),显著高于安慰剂。

关键数值与推荐

  • 共纳入16项随机对照试验,2754名绝经后骨质疏松症女性。
  • 依降钙素联合治疗疼痛评分WMD为-18.93(95%CI -23.97至-13.89)。
  • 依降钙素单药治疗疼痛评分WMD为-13.72(95%CI -19.51至-7.94)。
  • 依降钙素单药治疗并发症率POR为8.413(95%CI 2.031至34.859)。
  • 非降钙素药物并发症率Peto OR为7.450(95%CI 1.479至37.530)。

临床怎么用

  • 基于当前证据,依降钙素联合治疗可考虑用于治疗绝经后骨质疏松症。
  • 依降钙素联合治疗在疼痛缓解和并发症方面有益。
  • 依降钙素联合治疗与非降钙素药物相比,骨折率和骨密度变化相当。
  • 需要进一步试验研究依降钙素的配方和剂量。

局限性

  • 需要进一步试验研究依降钙素的配方和剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination therapies of elcatonin (C-E). INTRODUCTION: Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. METHODS: This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they independently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. RESULTS: Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change. Yet, C-E (WMD, - 18.93; 95% CI, - 23.97 to - 13.89) and M-E (WMD, - 13.72; 95% CI, - 19.51 to - 7.94) had significantly lower pain score than non-elcatonin medications. However, M-E (POR = 8.413, 95% CI, 2.031 to 34.859) and non-elcatonin medication (Peto OR, 7.450; 95% CI, 1.479 to 37.530) had significantly higher complication rates than placebo. No evidence detected inconsistency and small study effect in this network model. CONCLUSIONS: Based on current evidence, C-E may be considered for treating postmenopausal osteoporosis because it benefits on pain relief and complications. Moreover, it shows comparable fracture rate and bone mineral density change as compared with anti-osteoporosis and calcium supplements. Nevertheless, further trials are needed to investigate formula and dosages of elcatonin.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen WC, Lin EY, Kang YN, et al. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials. Osteoporos Int. 2019. PMID: 31041475. doi:10.1007/s00198-019-04997-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。